CSL is a leading global biotechnology company with a portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives.
CSL is headquartered in Melbourne, Australia. Our global R&D activities support our existing licensed products and development of new therapies that align with our technical and commercial capabilities in Immunology and Neurology, Haematology and Thrombosis, Transplant, Respiratory, Cardiovascular and Metabolic. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people.